---
document_datetime: 2025-10-09 14:03:53
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zadenvi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: zadenvi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6530803
conversion_datetime: 2025-12-30 10:42:04.060982
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zadenvi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                      |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------|
| Variation type IB /  | This was an application for a group of | 03/10/2025                          |                                             | SmPC,                            | To update Section 5.1 of the SmPC to include |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000296770   | variations. C.I.2 Change(s) Characteristics, of a generic/hybrid/biosimilar products following change for Implementation new additional submitted   | Labelling and PL   | information on the safety and effectiveness of the product based on a study conducted in paediatric patients with glucocorticoid-induced osteoporosis. This update follows the assessment and approval of the same change for the reference product, Prolia. To update Section 4.4 of the SmPC to add a warning about the reduction in bone mineral density following discontinuation of denosumab. This change implements wording agreed by the CHMP, following the outcome of PSUSA/00000954/202409.   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| discontinuation of denosumab. This change implements wording agreed by the CHMP, following the outcome of PSUSA/00000954/202409. Additionally, the MAH has implemented editorial changes throughout the PI to correct typographical errors and ensure alignment with the QRD template.   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|